Applies to Employer plans.
Not coveredThis policy covers Ozempic only for Type 2 Diabetes Mellitus. Coverage for non-diabetic indications including CV risk reduction is found in related policy #572. The diabetes policy does reference ASCVD as a qualifying condition to bypass metformin step therapy, but does not separately authorize a CV risk reduction indication.
Policy note: CV risk reduction as a standalone indication for Ozempic is not addressed by this policy; this policy is exclusively for T2DM. CV risk reduction coverage would be governed by related policy #572.
Policy effective May 1, 2026 · verified June 2, 2026 · source: 056%20 Glucagon Like%20 Peptide 1%20(GLP-1)%20 Receptor%20 Agonists%20and%20 Related%20 Drugs%20for%20the%20 Treatment%20of%20 Type%202%20 Diabetes · View policy document (PDF)